We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.41 | 1.24% | 33.47 | 33.50 | 33.55 | 33.47 | 33.33 | 33.33 | 2,397 | 15:52:06 |
From May 2019 to May 2024
By Olivia Bugault
Merck KGaA said Tuesday that it has invested 100 million euros ($108.9 million) for the construction of a new facility in California that will increase its gene therapy capacity.
The German pharmaceuticals and chemicals company said the facility, which should open next year, will be used for its BioReliance(R) viral and gene therapy service offering.
Merck KGaA already has a facility in California manufacturing gene therapies.
"Merck's new, 140,000-square-foot manufacturing facility will support viral and gene therapy production at the 1000-liter scale using its Mobius(R) single-use equipment," it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
April 21, 2020 08:52 ET (12:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
